You are here

Amgen Symposium: anemia in breast cancer – what is new?

By Xavier Pivot, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

23 - Xavier Pivot ANG

In his presentation, Xavier Pivot discusses anemia and fatigue. He provides an overview of the history of epoetin use which, about ten years ago, was massively prescribed as it had shown better and more regular outcomes in fighting anemia than transfusions. The improvement of haemoglobin levels reduced fatigue, the main anemia symptom, and thus improved cancer patients’ quality of life. However, problems such as thrombosis that are related to epoetin, especially at high doses, led to a decreased use. Xavier Pivot concludes that epoetin is indispensable for ensuring a good quality of life, but appropriate dosing is crucial.

 

Xavier Pivot, CHU, Besançon, France

Search this site

Featured videos

Free access to ebooks on cachexia and CINV

 

Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

and
Cancer cachexia: mechanisms and progress in treatment

 

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share